Redistribution of a murine humoral immune response following removal of an immunodominant B cell epitope from a recombinant fusion protein

doi:10.1016/0161-5890(93)90144-Z

Molecular Immunology

Volume 30, Issue 8, June 1993, Pages 733-739

https://doi.org/10.1016/0161-5890(93)90144-Z Get rights and content

Abstract

Immunization of different mice strains with a recombinant fusion protein composed of the vector-encoded N-terminal leader peptide CroLac (containing lambda Cro and Lad fragments) and a part of the transmembrane protein of HIV-1 (gp41) led to a high anti-CroLac humoral immune response. A detailed analysis of this response revealed the presence of an immunodominant, linear B cell epitope localized near the C-terminus of the CroLac fragment. The immune response seemed to be biased towards this epitope since few or no monoclonal antibodies (mAb) could be generated against the remaining part of CroLac and the gp41 fragment. Upon removal of the immunodominant region from the fusion protein the immune response was redirected and spread over the previously non-immunogenic regions. Consequently, we report a model system in which an immunodominant B cell epitope biases the immune response away from less immunogenic epitopes on the same molecule.

References (20)

R. Holmdahl et al.
A rapid an efficient immunization protocol for production of monoclonal antibodies reactive with autoantigens
J. Immun. Meth.
(1985)
E. Remaut et al.
Plasmid vectors for high efficiency expression, controlled by the p_l promoter of coliphage lambda
Gene
(1981)
H. Rink
Co valent linking of Fmoc amino acid residues to resin for solid phase peptide synthesis
Tetrahedron Lett.
(1987)
E. Atherton et al.
Solid Phase Peptide Synthesis
(1989)
M.P. Cancro et al.
B cell repertoire ontogeny: Heritable but dissimilar development of parental and F1 repertoires
J. Immun.
(1981)
T.F. Gajewski et al.
Antiprohfer-ative effect of IFN-g in immune regulation. III. Differential selection of TH1 and TH2 murine helper T lymphocyte clones using recombinant IL-2 and recombinant IFN-g
J. Immun.
(1989)
H.M. Geysen et al.
Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid
L.A. Herzenberg et al.
Epitope-specific regulation. I. Carrier induction of suppression for IgG anti-hapten antibody responses
J. exp. Med.
(1982)
E. Hochuli et al.
Genetic approach to facilitate purification of recombinant proteins with a novel metalchelate adsorbent
Bio I Technology
(1988)
M. Léonetti et al.
Immunization with a peptide having both T cell and conformationally restricted B cell epitopes elicits neutralizing antisera against a snake neurotoxin
J. Immun.
(1990)

There are more references available in the full text version of this article.

Cited by (22)

Engineering filamentous phage carriers to improve focusing of antibody responses against peptides
2010, Vaccine
Citation Excerpt :
Furthermore, it is not clear whether Ab responses elicited by the carrier affect or skew the Ab response against the targeted antigen. Several studies have shown that altering an immunodominant epitope (e.g., by point mutation or glycosylation) can redirect Ab responses to other epitopes on a peptide or protein [1,5–8] and can affect neutralizing activity [9]. However, to our knowledge no studies have addressed the possibility of altering a carrier protein's epitopes to improve the Ab response to an associated hapten, peptide or carbohydrate antigen.
The filamentous bacteriophage are highly immunogenic particles that can be used as carrier proteins for peptides and presumably other haptens and antigens. Our previous work demonstrated that the antibody response was better focused against a synthetic peptide if it was conjugated to phage as compared to the classical carrier, ovalbumin. We speculated that this was due, in part, to the relatively low surface complexity of the phage. Here, we further investigate the phage as an immunogenic carrier, and the effect reducing its surface complexity has on the antibody response against peptides that are either displayed as recombinant fusions to the phage coat or are chemically conjugated to it. Immunodominant regions of the minor coat protein, pIII, were removed from the phage surface by excising its N1 and N2 domains (Δ3 phage variant), whereas immunodominant epitopes of the major coat protein, pVIII, were altered by reducing the charge of its surface-exposed N-terminal residues (Δ8 phage variant). Immunization of mice revealed that the Δ3 variant was less immunogenic than wild-type (WT) phage, whereas the Δ8 variant was more immunogenic. The immunogenicity of two different peptides was tested in the context of the WT and Δ3 phage in two different forms: (i) as recombinant peptides fused to pVIII, and (ii) as synthetic peptides conjugated to the phage surface. One peptide (MD10) in its recombinant form produced a stronger anti-peptide antibody response fused to the WT carrier compared to the Δ3 phage carrier, and did not elicit a detectable anti-peptide response in its synthetic form conjugated to either phage carrier. This trend was reversed for a different peptide (4E10_L), which did not produce a detectable anti-peptide antibody response as a recombinant fusion; yet, as a chemical conjugate to Δ3 phage, but not WT phage, it elicited a highly focused anti-peptide antibody response that exceeded the anti-carrier response by ∼65-fold. The results suggest that focusing of the antibody response against synthetic peptides can be improved by decreasing the antigenic complexity of the phage surface.
Vaccination of mice with plasmids expressing processed capsid protein of foot-and-mouth disease virus-Importance of dominant and subdominant epitopes for antigenicity and protection
2007, Vaccine
Citation Excerpt :
In parallel with variations in the G–H loop extensive variation in a discontinuous epitope (site D) has been observed [26]. Previous studies have shown that removing dominant epitopes can redirect the immune response towards less dominant epitopes [4,27]. In this study we have selectively modified recombinant FMDV antigen at two of the most variable and antigenic epitopes on the virus particle, and studied the influence of these changes on the immune response.
The capsid of foot-and-mouth disease virus (FMDV) displays several independent B cell epitopes, which stimulate the production of neutralising antibodies. Some of these epitopes are highly variable between virus strains, but dominate the immune response. The site A on VP1 is the most prominent example of a dominant and variable site. This variability is a problem when designing vaccines against this disease, because it necessitates a close match between vaccine strain and virus in an outbreak. We have introduced a series of mutations into viral capsid proteins with the aim of selectively silencing two dominant and highly variable epitopes and thereby divert immune responses toward less dominant but more conserved, protective epitopes. When mice were immunized with modified antigens, the resulting immune responses showed a higher degree of cross-reactivity towards heterologous virus as compared to mice vaccinated with wild type epitopes. Most of the modifications did not adversely affect the ability of the plasmids to induce complete protection of mice against homologous challenge.
Strategies for mapping neutralizing epitopes: One way and two sides
2006, Vaccine
Candidate peptide-vaccine induced potent protection against CSFV and identified a principal sequential neutralizing determinant on E2
2006, Vaccine
Previously, two candidate multi-peptide-vaccines (MPVs) consisted of five overlapping synthetic peptides covering the antigenic domain B/C (aa693–777) on envelope protein E2 were prepared in our lab. And they successfully induced peptide-specific neutralizing antibodies and provided pigs with complete protection from the lethal challenge of virulent classical swine fever virus (CSFV) strain Shimen. In this study, these five peptides were conjugated to bovine serum albumin (BSA), with which five groups of pigs (n = 10) were inoculated, respectively. Among these candidate peptide-vaccines (PVs), PV-BC1 (BC1: aa693–716) exhibited the most potent protective activity, PV-BC3, PV-BC4 and PV-BC5 (BC3: aa723–745; BC4: aa741–760; BC5: aa757–777) had weaker effects, while no effect of PV-BC2 (BC2: aa712–727) had been detected. Moreover, the polyclonal antibodies induced by PV-BC1 and PV-BC4 were capable of neutralizing C-strain virus in vitro. Thus, a principal sequential neutralizing determinant (aa693–716) and a minor sequential neutralizing determinant (aa741–760) were proved to lie in the antigenic domain B/C, which can be recruited into developing more effective “marker vaccine” by epitope-vaccine strategy. Our study also indicates that scanning with a panel of sequential peptide-immunogens is an effective method to locate sequential neutralizing epitopes.
Generating conformation and complex-specific synthetic antibodies
2017, Methods in Molecular Biology
The evolution within us
2015, Philosophical Transactions of the Royal Society B: Biological Sciences

View all citing articles on Scopus

View full text

Redistribution of a murine humoral immune response following removal of an immunodominant B cell epitope from a recombinant fusion protein

Abstract

J. Immun. Meth.

Gene

Tetrahedron Lett.

Solid Phase Peptide Synthesis

B cell repertoire ontogeny: Heritable but dissimilar development of parental and F1 repertoires

J. Immun.

Antiprohfer-ative effect of IFN-g in immune regulation. III. Differential selection of TH1 and TH2 murine helper T lymphocyte clones using recombinant IL-2 and recombinant IFN-g

J. Immun.

Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid

Epitope-specific regulation. I. Carrier induction of suppression for IgG anti-hapten antibody responses

J. exp. Med.

Genetic approach to facilitate purification of recombinant proteins with a novel metalchelate adsorbent

Bio I Technology

Immunization with a peptide having both T cell and conformationally restricted B cell epitopes elicits neutralizing antisera against a snake neurotoxin

J. Immun.